← All trials
NCT04304053
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2020
- Primary completion
- Jun 15, 2020
- Completion date
- Jun 15, 2020
- First posted
- Mar 11, 2020
- Last posted
- Apr 16, 2020
- Enrollment
- 3040
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacio Lluita Contra la SIDALead sponsor
- Badalona Hospital Germans Trias i PujolReponsible party - principal investigator
- Badalona Hospital Germans Trias i PujolCollaborator
- Government of SpainCollaborator
- Institut Catala de SalutCollaborator
- FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIACollaborator
- Gebro Pharma GmbHCollaborator
- Laboratorios RubióCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.